These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 14717916)

  • 1. Thrombospondin-1 is a major activator of TGF-beta in fibrotic renal disease in the rat in vivo.
    Daniel C; Wiede J; Krutzsch HC; Ribeiro SM; Roberts DD; Murphy-Ullrich JE; Hugo C
    Kidney Int; 2004 Feb; 65(2):459-68. PubMed ID: 14717916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense oligonucleotides against thrombospondin-1 inhibit activation of tgf-beta in fibrotic renal disease in the rat in vivo.
    Daniel C; Takabatake Y; Mizui M; Isaka Y; Kawashi H; Rupprecht H; Imai E; Hugo C
    Am J Pathol; 2003 Sep; 163(3):1185-92. PubMed ID: 12937160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombospondin peptides are potent inhibitors of mesangial and glomerular endothelial cell proliferation in vitro and in vivo.
    Hugo CP; Pichler RP; Schulze-Lohoff E; Pröls F; Adler S; Krutsch HC; Murphy-Ullrich JE; Couser WG; Roberts DD; Johnson RJ
    Kidney Int; 1999 Jun; 55(6):2236-49. PubMed ID: 10354272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic expression patterns of transforming growth factor-beta(2) and transforming growth factor-beta receptors in experimental glomerulonephritis.
    Hartner A; Hilgers KF; Bitzer M; Veelken R; Schöcklmann HO
    J Mol Med (Berl); 2003 Jan; 81(1):32-42. PubMed ID: 12545247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic control of angiotensin II ameliorates renal disease while reducing renal TGF-beta in experimental mesangioproliferative glomerulonephritis.
    Zoja C; Abbate M; Corna D; Capitanio M; Donadelli R; Bruzzi I; Oldroyd S; Benigni A; Remuzzi G
    Am J Kidney Dis; 1998 Mar; 31(3):453-63. PubMed ID: 9506682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombospondin-2 therapy ameliorates experimental glomerulonephritis via inhibition of cell proliferation, inflammation, and TGF-beta activation.
    Daniel C; Wagner A; Hohenstein B; Hugo C
    Am J Physiol Renal Physiol; 2009 Nov; 297(5):F1299-309. PubMed ID: 19726547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene therapy by transforming growth factor-beta receptor-IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis.
    Isaka Y; Akagi Y; Ando Y; Tsujie M; Sudo T; Ohno N; Border WA; Noble NA; Kaneda Y; Hori M; Imai E
    Kidney Int; 1999 Feb; 55(2):465-75. PubMed ID: 9987071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombospondin 1 mediates angiotensin II induction of TGF-beta activation by cardiac and renal cells under both high and low glucose conditions.
    Zhou Y; Poczatek MH; Berecek KH; Murphy-Ullrich JE
    Biochem Biophys Res Commun; 2006 Jan; 339(2):633-41. PubMed ID: 16310163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Role of TGF-beta in glomerular diseases].
    Okuda S
    Nihon Rinsho; 1992 Dec; 50(12):3032-7. PubMed ID: 1491456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis.
    Peters H; Daig U; Martini S; Rückert M; Schäper F; Liefeldt L; Krämer S; Neumayer HH
    Kidney Int; 2003 Aug; 64(2):509-18. PubMed ID: 12846746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transforming growth factor-beta 1 is the predominant paracrine inhibitor of macrophage cytokine synthesis produced by glomerular mesangial cells .
    Kitamura M; Sütö T; Yokoo T; Shimizu F; Fine LG
    J Immunol; 1996 Apr; 156(8):2964-71. PubMed ID: 8609417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo transfer of engineered macrophages into the glomerulus: endogenous TGF-beta-mediated defense against macrophage-induced glomerular cell activation.
    Sütö TS; Fine LG; Shimizu F; Kitamura M
    J Immunol; 1997 Sep; 159(5):2476-83. PubMed ID: 9278341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nitric oxide and cGMP-dependent protein kinase regulation of glucose-mediated thrombospondin 1-dependent transforming growth factor-beta activation in mesangial cells.
    Wang S; Shiva S; Poczatek MH; Darley-Usmar V; Murphy-Ullrich JE
    J Biol Chem; 2002 Mar; 277(12):9880-8. PubMed ID: 11784717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PDE-5 inhibition impedes TSP-1 expression, TGF-beta activation and matrix accumulation in experimental glomerulonephritis.
    Hohenstein B; Daniel C; Wittmann S; Hugo C
    Nephrol Dial Transplant; 2008 Nov; 23(11):3427-36. PubMed ID: 18596129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombospondin 1 precedes and predicts the development of tubulointerstitial fibrosis in glomerular disease in the rat.
    Hugo C; Shankland SJ; Pichler RH; Couser WG; Johnson RJ
    Kidney Int; 1998 Feb; 53(2):302-11. PubMed ID: 9461090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix.
    Okuda S; Languino LR; Ruoslahti E; Border WA
    J Clin Invest; 1990 Aug; 86(2):453-62. PubMed ID: 2200803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stimulation of soluble guanylyl cyclase inhibits mesangial cell proliferation and matrix accumulation in experimental glomerulonephritis.
    Hohenstein B; Daniel C; Wagner A; Stasch JP; Hugo C
    Am J Physiol Renal Physiol; 2005 Apr; 288(4):F685-93. PubMed ID: 15561976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transforming growth factor-beta receptors in self-limited vs. chronic progressive nephritis in rats.
    Watanabe T; Yamamoto T; Ikegaya N; Fujigaki Y; Suzuki H; Togawa A; Fukasawa H; Nagase M; Hishida A
    J Pathol; 2002 Nov; 198(3):397-406. PubMed ID: 12375273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glomerular activin A overexpression is linked to fibrosis in anti-Thy1 glomerulonephritis.
    Gaedeke J; Boehler T; Budde K; Neumayer HH; Peters H
    Nephrol Dial Transplant; 2005 Feb; 20(2):319-28. PubMed ID: 15673690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis.
    Huang Y; Haraguchi M; Lawrence DA; Border WA; Yu L; Noble NA
    J Clin Invest; 2003 Aug; 112(3):379-88. PubMed ID: 12897205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.